Clinical Takeaway
Clinical trials show that cannabis-based products with higher THC content provide modest but measurable reductions in chronic pain compared to placebo. Evidence quality varies by product type, THC-to-CBD ratio, and delivery method, meaning no single cannabis formulation works for every pain condition. Patients and clinicians should weigh these modest benefits against known risks when considering cannabinoids as part of a chronic pain management plan.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review addresses a critical clinical gap by synthesizing current evidence on cannabinoid efficacy and safety for chronic pain management, where traditional analgesics often prove inadequate or carry significant adverse effects. The updated analysis through July 2025 provides clinicians with current risk-benefit data necessary to inform evidence-based decision-making regarding cannabis-based products as adjunctive or alternative pain therapies. Stratification by THC-to-CBD ratios enables more precise clinical application by identifying which cannabinoid formulations demonstrate efficacy for specific pain conditions.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
? This updated systematic review reinforces what many of us observe in practice: the evidence for cannabinoids in chronic pain remains genuinely mixed and heterogeneous. The restriction to randomized placebo-controlled trials is methodologically sound, yet we should acknowledge that chronic pain populations are inherently diverse, trial durations are often short relative to real-world treatment courses, and the THC-to-CBD ratio categorization, while useful, may oversimplify the complex pharmacology driving individual patient responses. Critically, publication bias and the historical paucity of large-scale, industry-independent trials continue to limit our ability to draw firm conclusions about long-term efficacy and safety profiles across different pain conditions. For the clinician, this means we should maintain a posture of cautious empiricism: cannabis-based products may offer benefit for selected patients with refractory chronic pain who have exhausted conventional options, but shared decision-making must explicitly address the evidence gaps, individual variability in response, and the need for clear therapeutic targets and exit criteria
Have thoughts on this? Share it:
